
The Food and Drug Administration granted a breakthrough therapy designation to inavolisib plus Ibrance and fulvestrant for HR-positive, HER2-negative locally advanced or metastatic breast cancer.

The Food and Drug Administration granted a breakthrough therapy designation to inavolisib plus Ibrance and fulvestrant for HR-positive, HER2-negative locally advanced or metastatic breast cancer.

My sister and I have learned to focus on the present day after a rollercoaster ride of remission, a cure and recurrence of stage 4 Hodgkin lymphoma.

Aerobic and strength training exercises may help preserve physical functioning in older adults with early-stage breast cancer who received chemotherapy.

With my breast cancer experience, there's always a juxtaposition between the fear of mortality and the hope of living.

Onivyde did not outperform chemotherapy in improving outcomes for patients with relapsed small cell lung cancer, despite having better response rates.

An Alzheimer’s drug did not have an effect on cognitive function in breast cancer survivors. However, one researcher noted reasons why there is still hope.

When I received news of a fellow blogger’s demise, I was heartbroken.

Safety data further support datopotamab deruxtecan as a new treatment option in metastatic hormone receptor–positive, HER2-negative breast cancer.

Throughout my experience with stage 4 non-Hodgkin lymphoma, I realized that time is precious to me.

Most patients with locally advanced vulvar cancer who received chemotherapy and IMRT experienced a disappearance of their cancer.

Stereotactic body radiotherapy and hormone treatment resulted in 40.1% 12-month progression-free survival in a recent study.

My relationship with my body has changed over the years, especially during and after breast cancer. Now, I have accepted the way I look.

Patients with high-risk early-stage non-small cell lung cancer who underwent surgery reported similar quality of life outcomes as those who had radiation.

Adding Truqap to Faslodex improved outcomes in patients with locally advanced or metastatic HR-positive, HER2-negative breast cancer.

I hope my poem — which outlines my experience being diagnosed with colon cancer — brings light to someone’s day.

Jill May, B.S.N., RN, OCN, shows her commitment to her patients and their caregivers through acts of kindness and compassion — especially during tough times.

One night, I had a dream that I played chess with Death and well, I won.

Dayna Hardee, RN, encourages patients, letting them know that someone has their back, someone is praying for them and someone is responding when they have a need.

Tecvayli responses were found to be slightly lower in patients with relapsed/refractory myeloma treated with another BCMA-targeted therapy.

When it comes to high blood sugar, cancer and diabetes can create a “vicious cycle,” as one expert explained.

I use affirmation as a technique to turn my negative thoughts about colon cancer into positive ones. Now, I see cancer as a blessing in disguise.

From Olivia Munn opening up about undergoing a hysterectomy and egg retrieval to Michael McDonald’s learned lesson after his wife’s cancer, here’s what’s going on in the oncology space this week.

A breakthrough therapy designation was granted to petosemtamab by the FDA to treat patients with recurrent or metastatic head and neck cancers.

The Food and Drug Administration approved Imdelltra (tarlatamab) for the treatment of patients with advanced small cell lung cancer that progressed on or after a platinum-based chemotherapy.

The postsurgical combination of androgen deprivation therapy and Erleada has shown promising results in prostate cancer.

Ignoring fear and anxiety only allows them to grow until they explode into a full-blown anxiety attack. It’s okay to be scared about cancer progression.

The addition of Tecentriq to chemotherapy did not improve overall survival in patients with relapsed triple-negative breast cancer.

These poems encapsulated my successful battle with stage 4 Hodgkin lymphoma.

The Food and Drug Administration approved Breyanzi for patients with pretreated, relapsed or refractory follicular lymphoma.

With smaller radiation beams, intensity-modulated radiation therapy “takes precision to the next level” for patients with prostate, an expert told CURE®.